Table 1.

Patient characteristics

VariablePatients, n=855 (%)
Sex
 Men546 (63.9)
 Women309 (36.1)
Age, yr
 Median57 (45–66)
Ethnicity
 White305 (35.7)
 Black, Asian, and minority ethnic550 (64.3)
Cause of ESKD
 ADPKD82 (9.6)
 GN235 (27.5)
 Diabetic nephropathy199 (23.3)
 Urologic50 (5.8)
 Unknown213 (24.9)
 Other76 (8.9)
Time at ESKD
 Pre-emptive172 (20.1)
 Dialysis dependence683 (79.9)
 Median time, yr1.7 (0.2–3.5)
Timing post-transplant, yr
 ≤1191 (22.3)
 >1664 (77.7)
 Median time3.7 (1.1–7.8)
Type of graft
 Deceased donor transplant516 (60.4)
 Living donor transplant276 (32.3)
 Simultaneous pancreas-kidney transplant42 (4.9)
 Antibody-incompatible transplant21 (2.5)
Immunosuppression at diagnosis
 FK monotherapy512 (59.9)
 FK and MMF187 (21.9)
 FK and steroids44 (5.1)
 FK, MMF, and steroids111 (13.0)
 Other1 (0.1)
Induction agent used
 Alemtuzumab766 (89.6)
 IL-2 receptor blocker89 (10.4)
History of rejection
 Yes115 (13.5)
 No740 (86.5)
Transplant number
 First761 (89.0)
 Greater than or equal to second graft94 (11.0)
Diabetes
 Yes312 (36.5)
 No543 (63.5)
  • ADPKD, autosomal dominant polycystic kidney disease; FK, tacrolimus; MMF, mycophenolate mofetil.